toxylact: a03ca04 otolonium bromide and psycholeptics

The first professional lActological database in the word

This web-page monograph summarizes toxicological–lactological information on drugs classified in ATC A03CA04, i.e. combinations of otilonium bromide with psycholeptics, for use by healthcare professionals.medpedia.framar+3

Classification and composition

Drugs in ATC class A03CA04 belong to “synthetic anticholinergic agents in combination with psycholeptics” and are used in functional gastrointestinal disorders.atcddd.fhi+2
The antispasmodic component is otilonium bromide, a quaternary ammonium synthetic anticholinergic with local spasmolytic action in the gastrointestinal tract, combined with one or more psycholeptics (sedative or anxiolytic agents).pharmakb+3

Mechanism of action and indication

Otilonium bromide acts primarily as an antimuscarinic and calcium-channel–blocking spasmolytic on smooth muscle of the gut, reducing intestinal motility, spasms and abdominal pain.drugbank+4
Psycholeptics in these combinations provide central sedative or anxiolytic effects, aiming to reduce visceral hypersensitivity and the impact of anxiety on symptom perception in irritable bowel syndrome and related motility disturbances.precision.fda+2

Therapeutic uses in adults

A03CA04 products are indicated for irritable bowel syndrome (IBS) and other functional gastrointestinal disorders characterized by abdominal pain, cramping and disturbed bowel motility with smooth muscle spasm.pubmed.ncbi.nlm.nih+4
They are used when non-pharmacological measures and single-agent antispasmodics are insufficient, especially in patients in whom anxiety or sleep disturbance aggravate IBS symptoms.sps+2

General toxicity profile

Otilonium bromide is poorly absorbed from the gut, with almost complete fecal excretion and very low systemic plasma levels, which limits systemic toxicity.e-lactation+1
Reported adverse events of otilonium-containing products include chest pain, dyspnea, palpitations, headache and asthenia, and rarely cardiovascular toxicity has been described in overdose situations.wikipedia+2

The psycholeptic components may contribute dose-dependent CNS depression, psychomotor impairment, and additive sedative effects when combined with alcohol or other depressants.medpedia.framar+2
In breastfeeding women, sedative co-medication increases the risk of maternal drowsiness and, at higher exposure, hypotonia or poor feeding in the infant, particularly if the psycholeptic is a benzodiazepine or strong sedative.mayoclinic+1

Contraindications and precautions

A03CA04 drugs are contraindicated in patients with hypersensitivity to otilonium bromide, the psycholeptic component, or excipients in the formulation.drugbank+1
As synthetic anticholinergics, they should be used cautiously, or avoided, in patients with narrow-angle glaucoma, urinary retention, significant prostatic hypertrophy or certain tachyarrhythmias, and psycholeptics require caution in severe respiratory insufficiency or hepatic impairment.pubmed.ncbi.nlm.nih+2

Adverse effects and monitoring

Commonly reported adverse effects with A03CA04 combinations include chest pain, shortness of breath, palpitations, headache and asthenia; gastrointestinal side effects are generally mild due to minimal systemic absorption of otilonium.e-lactation+2
For the psycholeptic component, clinicians should monitor for sedation, dizziness, cognitive slowing and, in rare cases, paradoxical agitation or dependency with long-term use, adjusting dose or discontinuing as clinically indicated.sps+1

Toxicity in overdose

Overdose with otilonium bromide has been associated in at least one report with cardiovascular toxicity, although such events are rare given its low systemic bioavailability at therapeutic doses.wikipedia+1
Overdose of the psycholeptic component can cause marked CNS depression, hypotension and respiratory compromise, so supportive care with cardiorespiratory monitoring is required and, where relevant, specific antidotes may be considered.mayoclinic+1

Pharmacokinetics relevant to lactation

Available data indicate that otilonium bromide is minimally absorbed, reaching plasma concentrations below 0.02 mg/L, with almost complete excretion unchanged in feces.e-lactation
This pharmacokinetic profile strongly suggests negligible transfer into breast milk, and an anticholinergic effect on milk production is unlikely at usual doses because of the poor systemic exposure.mayoclinic+1

Lactation safety assessment (otilonium component)

E‑lactation classifies otilonium bromide as “Very Low Risk – Compatible; not risky for breastfeeding or infant,” noting the absence of documented milk levels but very low maternal plasma concentrations.e-lactation
On this basis, short‑term use of oral otilonium bromide at standard therapeutic doses in breastfeeding women is considered acceptable, with routine clinical observation of the infant.mayoclinic+1

Lactation considerations (psycholeptic component)

Unlike otilonium, many psycholeptics show significant oral bioavailability and may reach measurable concentrations in breast milk, depending on lipophilicity, protein binding and half‑life.sps+1
Sedative psycholeptics are associated with potential infant effects such as drowsiness, poor suck, hypotonia and, in very rare cases, respiratory depression, particularly in premature or medically fragile infants.sps+1

Clinical recommendations in breastfeeding

When an A03CA04 combination is considered in a breastfeeding mother, a first step is to evaluate whether non-sedating antispasmodics (e.g. peppermint oil, hyoscine butylbromide, mebeverine) could provide adequate control of IBS symptoms.breastfeedingnetwork+2
If the combination is deemed necessary, select the lowest effective dose, prefer psycholeptics with shorter half‑life and better lactation data, and monitor the infant for changes in feeding, sleep, behavior or breathing, especially in the first days of treatment.sps+1

Use in special populations

Exposure to medications via breast milk carries higher risk in premature neonates, newborns and infants with significant renal, hepatic or cardiorespiratory disease; in these groups, sedative combinations should be avoided whenever possible.mayoclinic+1
In healthy term infants, otilonium alone appears acceptable, but addition of a psycholeptic mandates individualized risk–benefit assessment, considering maternal symptom burden and alternative therapies.e-lactation+2

Regulatory and prescription status

A03CA04 preparations are prescription-only medicines, and the dose regimen must be individualized by a physician according to indication, age and comorbidities.drugcentral+2
Before initiating therapy in a breastfeeding woman, consultation with a healthcare professional experienced in hepatology/gastroenterology and perinatal pharmacology, or use of specialized lactation pharmacology resources, is advisable.e-lactation+2

Practical documentation note

For toxicological–lactological databases, otilonium bromide in A03CA04 should be tagged as “antispasmodic, synthetic anticholinergic, quaternary ammonium, very low lactation risk,” with a structured warning that overall product risk is driven by the psycholeptic partner.atcddd.fhi+3
Psycholeptic components should each receive separate entries with detailed lactation risk stratification, allowing clinicians to distinguish the relatively safe local gut spasmolytic from the systemically active sedative co‑medication.precision.fda+2

Recent ARTICLES

July 24

Abdominal Compartment Syndrome

PWhile the formal term and its consensus definitions were codified by the World Society of the Abdominal Compartment Syndrome (WSACS) only in the early 2000s, the physiological underpinnings have been observed for over 150 years. In 1863, the French physiologist Etienne-Jules Marey was the first to document the reciprocal relationship between intra-abdominal pressure (IAP) and respiratory function, noting that the expansion of the abdominal cavity directly impacted the efficiency of the thoracic bellows.

July 18

Assessment of Postoperative Fever

For the physician and the student of medicine, the assessment of postoperative fever is not merely a task of temperature monitoring, but a diagnostic journey that requires a nuanced understanding of immunology, physiology, and clinical timing. Guided by the principle of "Primum non nocere," this report seeks to bridge the gap between complex pathophysiological mechanisms and the empathetic care of the patient, providing a comprehensive framework for identifying, understanding, and managing this common clinical challenge.

July 14

Clinical Review of Congenital and Acquired Cystic Kidney Diseases

The healing arts, as envisioned by the ancient traditions of medicine, seek not merely the eradication of pathology but the restoration of a delicate equilibrium between the body’s internal environment and the external world. In the realm of nephrology, cystic diseases of the kidney represent a profound disruption of this balance.

Spotlight

A Comprehensive Analysis of Complement System Deficiencies in Pediatric and Adult Populations

The human immune system is a tapestry of ancient evolutionary mechanisms and highly specialized adaptive responses, woven together to maintain the delicate equilibrium of health. At the heart of this architecture lies the complement system, a complex network of over fifty proteins that function as the primordial vanguard of innate immunity. Named for its ability to "complement" the action of antibodies, this system serves as a bridge between the immediate, non-specific recognition of pathogens and the targeted, long-term memory of the adaptive immune response. However, when this sentinel falls silent due to genetic or acquired deficiencies, the result is a state of nuanced immunosuppression that significantly alters the human clinical landscape across all ages.